Final answer:
The medication Butorphanol would inhibit the analgesic effect of a fentanyl transdermal patch because it acts as a partial opioid agonist-antagonist, thereby reducing the efficacy of full opioid agonists like fentanyl.
Step-by-step explanation:
In the context of fentanyl transdermal patch being used for long term analgesia, the medication that would inhibit its analgesic effect is A. Butorphanol. Butorphanol is an opioid partial agonist-antagonist, and as such, it can reduce the effect of a full opioid agonist like fentanyl because it competes for the same opioid receptors without providing the same level of analgesic effect.
On the other hand, Hydromorphone (B), Morphine (C), and Dexmedetomidine (D) would not inhibit the analgesic effect of fentanyl. Hydromorphone and Morphine are both full opioid agonists, which means they would potentiate the painkilling effect rather than inhibit it. Dexmedetomidine is an alpha-2 adrenergic agonist, which possesses sedative properties but does not have a significant antagonist action at opioid receptors.Hydromorphone, which is a potent opioid analgesic, can inhibit the analgesic effect of fentanyl. It competes with fentanyl for binding to opioid receptors, potentially reducing the effectiveness of fentanyl as an analgesic.
Therefore, if a fentanyl transdermal patch is being used for long-term analgesia, hydromorphone should be avoided as it may interfere with the desired analgesic effect.